Armon Sharei is the founder and CEO of Portal Biotechnologies, a cell-engineering platform company in Watertown, Massachusetts that builds devices to push genetic and molecular cargo into living cells without killing them. He earned a chemical engineering PhD at MIT, where he invented the membrane-squeezing CellSqueeze technique, then founded SQZ Biotechnologies, raised more than $300M, struck a billion-dollar Roche partnership, and took the company public on the NYSE in 2020 before being ousted and watching it liquidate in 2024. After a sabbatical spent drawing comics about immune cells, he returned with Portal, choosing this time to sell tools rather than develop drugs, and has built a network of 100+ customers including most of the top 10 global pharma companies plus an $8M DARPA contract.
CellFE is an Alameda, California biotechnology company building microfluidics-based, non-viral cell-engineering instruments and consumables. Its Ryva mechanoporation platform squeezes cells through microfluidic channels to transiently open their membranes and deliver gene-editing payloads (mRNA, CRISPR-RNP, DNA vectors) in under 10 milliseconds, aiming to preserve cell health and viability where viral vectors and electroporation fall short. The goal is to make lifesaving cell therapies such as CAR-T faster, cheaper, and more scalable to manufacture.